WHITEHAWK THERAPEUTICS
Live / Applied — First extension granted (statement of use) (as of 09 Mar 2026)
What this means for you
Not registered yet, but its 21 Mar 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99097308
- Mark type
- Stylized text
- Filed
- 21 Mar 2025
- Published for opposition
- 23 Sept 2025
- Attorney of record
- Aaron D. Hendelman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment and prevention of cancer; pharmaceutical preparations for precision oncology; pharmaceutical preparations for the purpose of molecular profiling of tumors to identify targetable alterations; pharmaceutical preparations, namely, a drug formulation comprising antibody-drug conjugates (ADCs) for use in the field of oncology; pharmaceutical preparations, namely, a drug formulation comprising antibody-drug conjugates (ADCs) for use treating GI cancer, prostate cancer, cancer of the head and neck, endometrial cancer, cervical cancer, breast cancer, pancreatic cancer, central nervous system (CNS) tumors, solid tumors, non-small cell lung cancer (NSCLC), and ovarian cancer
- Class 042 — Scientific and technological services: Medical and scientific research in relation to precision oncology; medical and scientific research in relation to antibody-drug conjugates (ADCs) in the field of oncology; medical and scientific research for the purpose of molecular profiling of tumors to identify targetable alterations; medical and pharmaceutical research services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; scientific and technological services, namely, scientific research services in the field of process development, validation, qualification, and manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological services consultation services in the field of development, manufacturing and testing of pharmaceuticals and biopharmaceuticals; providing product research and development in the pharmaceutical field for purposes of drug discovery process development, drug discovery validation, drug discovery qualification, and drug discovery manufacturing of pharmaceuticals and biopharmaceuticals; scientific research and technological consultation services in the field of pharmaceutical research and pharmacology; custom development of pharmaceutical, biopharmaceutical and chemical products; providing evaluation and testing for pharmaceutical, biopharmaceutical and chemical products, and medical devices featuring testing for safety, toxicity, content, identity, purity, configuration and function for others, using chemical, in vitro or in vivo assays, analyses and models; pre-clinical and non-clinical evaluation and testing of pharmaceutical, biopharmaceutical and chemical products performed primarily using animals and other biological models; pharmaceutical, biopharmaceutical, and chemical research and development for others; pharmaceutical research in the field of oncology; pharmaceutical research in relation to GI cancer, prostate cancer, cancer of the head and neck, endometrial cancer, cervical cancer, breast cancer, pancreatic cancer, central nervous system (CNS) tumors, solid tumors, non-small cell lung cancer (NSCLC), and ovarian cancer
Owner
- Whitehawk Therapeutics, Inc., Morristown, NJ, US
- Whitehawk Therapeutics, Inc., Morristown, NJ, US
Prosecution history
- 10 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Mar 2026 — SOU EXTENSION 1 GRANTED
- 09 Mar 2026 — SOU EXTENSION 1 FILED
- 09 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 18 Nov 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 23 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 23 Sept 2025 — PUBLISHED FOR OPPOSITION
- 17 Sept 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Aug 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Aug 2025 — EXAMINER'S AMENDMENT ENTERED
- 21 Aug 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 21 Aug 2025 — EXAMINERS AMENDMENT E-MAILED
- 21 Aug 2025 — EXAMINERS AMENDMENT -WRITTEN
- 20 Aug 2025 — ASSIGNED TO EXAMINER
- 10 Jul 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED